Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
  • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
  • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
  • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
  • C07D231/38—Nitrogen atoms
  • C07D231/40—Acylated on said nitrogen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/415—1,2-Diazoles
  • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/425—Thiazoles
  • A61K31/428—Thiazoles condensed with carbocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
  • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
  • A61K31/445—Non condensed piperidines, e.g. piperocaine
  • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
  • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/47—Quinolines; Isoquinolines
  • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
  • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P11/00—Drugs for disorders of the respiratory system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P17/00—Drugs for dermatological disorders
  • A61P17/06—Antipsoriatics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P19/00—Drugs for skeletal disorders
  • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/02—Antineoplastic agents specific for leukemia
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to 3(5)-ureido-pyrazole derivatives, to a process for their preparation, to pharmaceutical compositions containing them and to their use as therapeutic agents, particularly in the treatment of cancer and proliferative disorders.
• cytotoxic drugs such as, e.g. fluorouracil (5-FU), doxorubicin and camptothecins, cause damage to DNA or to affect cellular metabolic pathways and thus cause, in many cases, an indirect block of the cell cycle. Therefore, by producing an irreversible damage to both normal and tumor cells, these agents result in a significant toxicity and side-effects.
• restriction points a family of enzymes known as the cyclin-dependent kinases (cdk).
• cdk cyclin-dependent kinases
• Checkpoint controls are defective in tumor cells due, in part, to disregulation of cdk activity. For example, altered expression of cyclin E and cdk's has been observed in tumor cells, and deletion of the cdk inhibitor p27 KIP gene in mice has been shown to result in a higher incidence of cancer.
• cdks are rate-limiting enzymes in cell cycle progression and, as such, represent molecular targets for therapeutic intervention.
• the direct inhibition of cdk/cyclin kinase activity should be helpful in restricting the unregulated proliferation of a tumor cell.
• 3-ureido-pyrazoles have cdk/cyclin kinase inhibitory activity and are thus useful in therapy as antitumor agents and lack, in terms of both toxicity and side effects, the aforementioned drawbacks of known antitumor drugs.
• the compounds of this invention are useful in the treatment of a variety of cancers including, but not limited to: carcinoma such as bladder, breast, colon, kidney, liver, lung, including small cell lung cancer, esophagus, gall-bladder, ovary, pancreas, stomach, cervix, thyroid, prostate, and skin, including squamous cell carcinoma; hematopoietic tumors of lymphoid lineage, including leukemia, acute lymphocitic leukemia, acute lymphoblastic leukemia, B-cell lymphoma, T-cell-lymphoma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, hairy cell lymphoma and Burkett's lymphoma; hematopoietic tumors of myeloid lineage, including acute and chronic myelogenous leukemias, myelodysplastic syndrome and promyelocytic leukemia; tumors of mesenchymal origin, including fibrosar
• these 3-ureido- pyrazole derivatives are also useful in the treatment of a variety of cell proliferative disorders such as, for instance, benign prostate hyperplasia, familial adenomatosis polyposis, neurofibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis and post-surgical stenosis and restenosis.
• the compounds of the invention may be useful in the treatment of Alzheimer's disease, as suggested by the fact that cdk5 is involved in the phosphorylation of tau protein (J. Biochem., 117, 741-749, 1995).
• the compounds of this invention may also useful in the treatment of cancer, viral infections, prevention of AIDS development in HIV-infected individuals, autoimmune diseases and neurodegenerative disorders.
• the compounds of this invention may also be useful in inhibiting tumor angiogenesis and metastasis.
• the compounds of this invention may also act as inhibitors of other protein kineses, e.g. protein kinase C, her2, rafl, MEK1, MAP kinase, EGF receptor, PDGF receptor, IGF receptor, PI3 kinase, weel kinase, Src, Abl and thus be effective in the treatment of diseases associated with other protein kineses.
• the present invention provides a method for the treatment of cell proliferative disorders associated with an altered cell dependent kinase activity, comprising administering to a mammal in need thereof an effective amount of a compound represented by formula (I):
• R is a C,-C 6 alkyl, aryl or arylalkyl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino,
• R is -(CH 2 ) n -R 3 ; n is 0 or an integer from 1 to 4;
• R 3 is hydrogen, hydroxy, amino, or it is selected from the group consisting of cycloalkyl, aryl and heterocyclyl, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N- carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsul
• R 2 is hydrogen, or
• R 2 and R together with the nitrogen atom to which they are bonded, form a heterocyclyl or heteroaryl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N- carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, ary
• the cell proliferative disorder is selected from the group consisting of cancer, Alzheimer's disease, viral infections, autoimmune diseases and neurodegenerative disorders.
• Examples of types of cancer that may be treated include carcinoma, squamous cell carcinoma, hematopoietic tumors of myeloid or lymphoid lineage, tumors of mesenchymal origin, tumors of the central and peripheral nervous system, melanoma, seminoma, teratocarcinoma, osteosarcoma, xenoderoma pigmentosum, keratoctanthoma, thyroid follicular cancer and Kaposi's sarcoma.
• the cell proliferative disorder is selected from the group consisting of benign prostate hyperplasia, familial adenomatosis polyposis, neuro-fibromatosis, psoriasis, vascular smooth cell proliferation associated with atherosclerosis, pulmonary fibrosis, arthritis glomerulonephritis, and post- surgical stenosis and restenosis.
• inventive method provides tumor angiogenesis and metastasis inhibition.
• inventive method may also provide cell cycle inhibition or cdk/cyclin dependent inhibition.
• the present invention also provides a 3-ureido-pyrazole derivative represented by formula (I):
• R is a C,-C 6 alkyl, aryl or arylalkyl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N-carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, arylamino,
• R is -(CH 2 ) n -R 3 ; n is 0 or an integer from 1 to 4;
• R 3 is hydrogen, hydroxy, amino, or it is selected from the group consisting of cycloalkyl, aryl and heterocyclyl, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N- carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsul
• R 2 is hydrogen, or
• R 2 and R together with the nitrogen atom to which they are bonded, form a heterocyclyl or heteroaryl group, which is optionally substituted with one or more hydroxy, halogen, nitro, cyano, oxo, carboxy, amino, alkylamino, dialkylamino, alkylcarbonylamino, alkoxycarbonylamino, alkoxycarbonylalkylamino, aminocarbonylalkylamino, N-alkyl-N- carbonylamino, N-cycloalkyl-N-alkylaminoalkyl, aminoalkyl, aminocarbonyl, alkyl, cycloalkyl, alkylthio, alkoxy, alkylcarbonyl, alkylsulphonyl, alkylsulphonylamino, aminosulphonyl, alkoxycarbonyl, aryl, arylalkyl, aryloxy, arylthio, arylsulphonyl, ary
• the present invention also provides a process for preparing the 3-ureido-pyrazole derivative, or a pharmaceutically acceptable salt thereof, by:
• the present invention also provides a process for preparing the 3-ureido-pyrazole derivative, or a pharmaceutically acceptable salt thereof, by:
• R, R, and R 2 are as defined above;
• the present invention also provides a pharmaceutical composition, comprising the 3- ureido-pyrazole derivative and at least one pharmaceutically acceptable carrier and/or diluent.
• 3-ureido-pyrazole derivatives are known in the art as pesticides, herbicides or even as therapeutic agents. Among them are, as an example, heteroaryl-pyrazoles active as p38 kinase inhibitors (WO 9852941, G.D. Searle and Co.). Aryl-ureido-pyrazoles such as, for instance, phenyl-ureidopyrazoles are also known in the art as p38 kinase inhibitors (WO 99/32111, Bayer Co.). Several 5-aryl-(lH-pyrazol-5-yl)-urea derivatives are known in the art as neuropeptide Y antagonists useful as hypolipemic agents (WO 98//24768, Banyu pharmaceutical Co.).
• halogen atom includes a fluorine, chlorine, bromine or iodine atom.
• alkyl and alkoxy include C,- C 6 alkyl and C,-C 6 alkoxy groups.
• the term straight or branched C,-C 6 alkyl or C,-C 6 alkoxy group includes a group selected from, methyl, ethyl, npropyl. isopropyl, n-butyl, isobutyl, sec-butyl, tertbutyl, n-pentyl, n-hexyl, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy and the like.
• alkylthio, alkylamino, dialkylamino, alkoxycarbonyl, alkoxycarbonylamino, alkylcarbonyl, alkylsulphonyl, alkoxycarbonyl, N-alkylpiperazinyl and the like we intend any of the aforementioned groups wherein the alkyl and alkoxy moieties stand for C,-C 6 alkyl or alkoxy groups.
• cycloalkyl includes a C 3 -C 6 cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl as well as cycloalkyl and bridged cycloalkyl groups with up to 10 carbon atoms.
• aryl stands for mono-, bi- or poly- carbocyclic or heterocyclic hydrocarbons with from 1 to 4 ring moieties, wherein at least one of the rings is aromatic, either fused or linked to each other by single bonds. These groups may have from 5 to 20 carbon atoms, preferably from 6 to 20 carbon atoms.
• aryl also include aromatic heterocycles otherwise referred to as heteroaryl groups.
• heterocycle refers to a 5 or 6 membered saturated or unsaturated carbocycle wherein one or more carbon atoms are replaced by one or more atoms selected from nitrogen, oxygen and sulphur.
• the number of heteroatoms is not limited and may be, for example, one, two, three, or more.
• aryl groups include phenyl, 1-naphtyl, 2-naphthyl, indanyl, indenyl, biphenyl, benzocycloalkyl, e.g. bicyclo[4.2.0]octa-l,3,5,-triene, benzoheterocyclyl, e.g.
• Example of heterocycles are pyrrolidine, piperidine, piperazine, morpholine and the like.
• C 2 -C 4 alkenyl or alkynyl includes a group selected from vinyl, allyl, 1- propenyl, isopropenyl, 1-butenyl, 2-butenyl. 3-butenyl, ethynyl. propynyl, butynyl and the like.
• perfluorinated alkyl group includes a C,-C 4 alkyl group further substituted by more than one fluorine atom such as, for instance, trifluoromethyl, 2,2,2-trifluoroethyl, 1,1,2,2,2-pentafluoroethyl and the like.
• Pharmaceutically acceptable salts of the compounds of formula (I) include the acid addition salts with inorganic or organic, e.g., nitric, hydrochloric, hydrobromic, sulphuric, perchloric, phosphoric, acetic, trifluoroacetic, propionic, glycolic, lactic, oxalic, malonic, malic, maleic, tartaric, citric, benzoic, cinnamic, mandelic, methanesulphonic, isethionic and salicylic acid, as well as the salts with inorganic or organic bases, e.g., alkali or alkaline-earth metals, especially sodium, potassium, calcium or magnesium hydroxides, carbonates or bicarbonates, acyclic or cyclic amines, preferably methylamine, ethylamine, diethylamine, triethylamine or piperidine.
• inorganic or organic bases e.g., alkali or alkaline-earth
• the compounds of formula (I) may have asymmetric carbon atoms and may therefore exist either as racemic admixtures or as individual optical isomers.
• Preferred compounds of the invention of formula (I), are those where R is a C 3 -C 6 cycloalkyl or an optionally substituted straight or branched C r C 4 alkyl group, a cycloalkyl or an aryl or arylalkyl group, and R, is a C,-C 4 alkyl group or a phenyl, phenylalkyl, heteroaryl, heteroarylalkyl or heterocyclyl group, each being optionally substituted as defined above.
• R is a C 3 -C 6 cycloalkyl and R, is a C,-C 4 alkyl group substituted by hydroxy or amino, or is an aryl, arylalkyl, heterocyclyl or heterocyclylalkyl, wherein the aryl or heterocyclyl moiety is selected from the group consisting of phenyl or optionally benzocondensed pyiridine, indole, thiophene, thiazole, isoxazole, furan, piperidine, morpholine, each optionally further substituted.
• Another class of preferred compounds of formula (I) are those where R, and R 2 form an optionally substituted heterocyclyl ring such as piperidino, piperazino or morpholino.
• the number of substituents is not particularly limited.
• the groups described above may be substituted with, for example, one, two, three, or more of the substituents.
• the substituents may be the same or different, i.e., they are indepedently selected.
• Examples of preferred compounds of the invention which may be in the form of a pharmaceutically acceptable salt, e.g., hydrobromide or hydrochloride salt, include the following:
• N-cyclobutyl-N'-(3 -cyclopenthyl-lH-pyrazol-5-yl)urea N-(3-cyclopenthyl lH-pyrazol-5-yl)-l-pyrrolidinecarboxamide
• N-(3-cyclopropyl-lH-pyrazol-5-yl)-N'-(3-aminophenyl)urea N-(3 -cyclopropyl- 1 H-pyrazol-5-yl)-N'-( 1 H-imidazol-6yl)urea; N-(3-cyclopropyl-lH-pyrazol-5-yl)-N'-(3-hydroxyphenyl)urea; N-(3-cyclopropyl- 1 H-pyrazol-5-yl)-N'-(4-hydroxyphenyl)urea.
• the compounds of formula (I) object of the present invention and the salts thereof can be obtained, for instance, by a process comprising: (a) reacting a compound of formula (II):
• R is defined as above;
• the compounds of formula (V) may be obtained by a process comprising:
• the compounds of formula (I) may alternatively be obtained by a process comprising:
• the compounds of formula (I) can alternatively be obtained by a process comprising: (a) reacting a compound of formula (V):
• the compounds of formula (I) can alternatively be obtained by a process comprising:
• the compounds of formula (I) can alternatively be obtained by a process comprising: (a) reacting the oxime resin (XVI) with triphosgene to give a polystyrene supported agent (XVII):
• reaction between a compound of formula (II) or formula (V) and a compound of formula (III) can be carried out in the presence of sodium hydrogen carbonate or a tertiary base, such as triethylamine, N-methylmo ⁇ holine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichioromethane, chloroform, diethylether, tetrahydrofuran, acetonitrile, dioxane or N,N-dimethylformamide, at a temperature ranging from about 10°C to reflux.
• sodium hydrogen carbonate or a tertiary base such as triethylamine, N-methylmo ⁇ holine, N,N-diisopropylethylamine or pyridine
• a suitable solvent such as toluene, dichioromethane, chloroform, diethylether, tetrahydrofuran,
• reaction of a compound of formula (IV) to give a compound of formula (I) can be carried out with a base such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate in a suitable solvent such as a mixture of methanol or ethanol and water at room temperature.
• a base such as sodium hydroxide, potassium hydroxide, sodium carbonate or potassium carbonate
• a suitable solvent such as a mixture of methanol or ethanol and water at room temperature.
• reaction of the compounds of formula (II) and the compounds of formula (III) to give the compounds of formula (XIII) can be carried out with a base such as sodium hydrogencarbonate or sodium hydrate in suitable solvent such as ethanol or methanol at room temperature.
• the reaction of the compounds of formula (XIII) to give the compounds of formula (I) can be carried out by heating at a temperature ranging from 60 to 80°C in presence of an excess of compounds of formula (III) in presence of a base such as sodium hydrate in a suitable solvent such as methanol or ethanol.
• reaction of a compound of formula (XIV) to give a compound of formula (I) can be carried out with an acid such as trifluoroacetic acid, hydrochloric acid, formic acid, in a suitable solvent such as methylene chloride at a temperature ranging from -10°C to room temperature.
• an acid such as trifluoroacetic acid, hydrochloric acid, formic acid
• a suitable solvent such as methylene chloride
• reaction of a compound of formula (IX) to give a compound of formula (X) may be carried out with acetonitrile and a base such as sodium hydride in a suitable solvent such as diethylether, tetrahydrofuran, dioxane at a temperature ranging from room temperature to 120°C.
• a base such as sodium hydride
• a suitable solvent such as diethylether, tetrahydrofuran, dioxane
• reaction of a compound of formula (X) to give a compound of formula (II) may be carried out with hydrazine hydrate, in a solvent such as methanol or ethanol at a temperature ranging from room temperature to 80°C.
• reaction of a compound of formula (II) to give a compound of formula (XI) may be carried out with oxone® (potassium peroxymonosulfate) or another oxidizing agent such as hydrogen peroxide in a suitable solvent such as a mixture of water-acetone at a temperature ranging from 0°C to room temperature.
• oxone® potassium peroxymonosulfate
• another oxidizing agent such as hydrogen peroxide
• reaction of a compound of formula (XI) to give a compound of formula (XII) may be carried out with terbutoxycarbonyl anhydride in a suitable solvent such as a mixture of methylene chloride-water at room temperature, in the presence of sodium hydrogen carbonate.
• reaction of a compound of formula (XII) to give a compound of formula (V) may be carried out directly with hydrogen in presence of a catalyst such as palladium on charcoal in a suitable solvent such as methanol or ethanol at room temperature.
• a catalyst such as palladium on charcoal in a suitable solvent such as methanol or ethanol at room temperature.
• the reaction of a compound of formula (V) to give a compound of formula (VI) may be carried out with 4-nitrophenyl chloroformate or a polymer supported form of it in the presence of a tertiary base such as triethylamine, N-methylmo ⁇ holine, N,N- diisopropylethylamine or pyridine, in a suitable solvent such as toluene, dichioromethane, chloroform, diethylether, tetrahydrofuran, acetonitrile, dioxane or N,N-dimethylformamide, at a temperature ranging from about -10°C to room temperature.
• a tertiary base such as triethylamine, N-methylmo ⁇ holine, N,N- diisopropylethylamine or pyridine
• a suitable solvent such as toluene, dichioromethane, chloroform, diethylether, tetrahydro
• reaction between a compound of formula (VI) or (XV) and a compound of formula (VII) to give a compound of formula (VIII) can be carried out in a suitable solvent such as toluene, dichioromethane, chloroform, diethylether, tetrahydrofuran, acetonitrile, dioxane or N,N-dimethylformamide, at a temperature ranging from about room temperature to reflux.
• a suitable solvent such as toluene, dichioromethane, chloroform, diethylether, tetrahydrofuran, acetonitrile, dioxane or N,N-dimethylformamide
• reaction of a compound of formula (VIII) to give a compound of formula (I) can be carried out with an acid such as trifluoroacetic acid, hydrochloric acid, formic acid, in a suitable solvent such as methylene chloride at a temperature ranging from -10°C to room temperature.
• an acid such as trifluoroacetic acid, hydrochloric acid, formic acid
• a suitable solvent such as methylene chloride
• reaction of a compound of formula (V) to give a compound of formula (XV) can be carried out with 1,1 '-carbonyldiimidazole, bis(trichloromethyl)carbonate or trichloromethyl chloroformate in the presence, if necessary, of a tertiary base such as tri ethyl amine, N,N-diisopropylethylamine or pyridine, in a suitable solvent such as dichioromethane, chloroform, toluene, dioxane or tetrahydrofuran at a temperature ranging from 0°C to reflux.
• a tertiary base such as tri ethyl amine, N,N-diisopropylethylamine or pyridine
• the reaction of the oxime resin (XVI) with triphosgene to give the compound of formula (XVII) can be carried out in a suitable solvent such as dichioromethane at room temperature.
• reaction of the compound of formula (XVII) with the compound of formula (II) to give a compound of formula (XVIII) can be carried out in a suitable solvent such as dichioromethane at room temperature.
• reaction of the compounds of formula (XVIII) with the compounds of formula (VII) to give the compounds of formula (I) can be carried out in a suitable solvent such as toluene, dichioromethane, chloroform, diethylether, tetrahydrofuran, acetonitrile, dioxane or N,N-dimethylformamide at a temperature ranging from room temperature to reflux.
• a suitable solvent such as toluene, dichioromethane, chloroform, diethylether, tetrahydrofuran, acetonitrile, dioxane or N,N-dimethylformamide
• the compounds of formula (I) are active as cdk/cyclin inhibitors as they gave positive results when tested according to the following procedure.
• the inhibiting activity of putative cdk/cyclin inhibitors and the potency of selected compounds was determined through a method of assay based on the use of the MultiScreen- PH 96 well plate (Millipore), in which a phosphocellulose filter paper was placed at each well bottom allowing binding of positive charged substrate after a washing/filtration step.
• Detection filters were allowed to dry at 37°C, then 100 -1/well scintillant were added and 33P labeled histone HI was detected by radioactivity counting in the Top-Count instrument.
• ATP and substrate concentrations were varied: 4, 8,12, 24, 48 -M for ATP (containing proportionally diluted P33g-ATP) and 0.4, 0.8, 1.2, 2.4, 4.8 -M for histone were used in absence and presence of two different, properly chosen inhibitor concentrations.
• the inhibiting activity of putative cdk/cyclin inhibitors and the potency of selected compounds was determined through a method of assay based on the use of a SPA (Scintillation Proximity Assay) 96 well plate assay.
• the assay is based on the ability of streptavidin coated SPA beads to capture a biotinylated peptide derived from a phosphorylation site of histone.
• IC50 values were calculated using a variation of the four parameter logistics equation:
• the compounds of formula (I) are therefore useful to restrict the unregulated proliferation of tumor cells, hence in therapy in the treatment of various tumors such as, for instance, carcinomas, e.g., mammary carcinoma, lung carcinoma, bladder carcinoma, colon carcinoma, ovary and endometrial tumors, sarcomas, e.g. soft tissue and bone sarcomas, and the hematological malignancies such as, e.g., leukemias.
• carcinomas e.g., mammary carcinoma, lung carcinoma, bladder carcinoma, colon carcinoma, ovary and endometrial tumors
• sarcomas e.g. soft tissue and bone sarcomas
• hematological malignancies such as, e.g., leukemias.
• the compounds of formula (I) are also useful in the treatment of other cell proliferative disorders such as psoriasis, vascular smooth cell proliferation associated with atherosclerosis and post-surgical stenosis and restenosis and in the treatment of Alzheimer's disease.
• the compounds of formula (I) of the present invention suitable for administration to a mammal, e.g., to humans, can be administered by the usual routes and the dosage level depends upon the age, weight, conditions of the patient and the administration route.
• a suitable dosage adopted for oral administration of a compound of formula (I) may range from about 10 to about 500 mg pro dose, from 1 to 5 times daily.
• the compounds of the present invention can be administered either as single agents or, alternatively, in combination with known anticancer treatments such as radiation therapy or chemotherapy regimen in combination with cytostatic or cytotoxic agents, antibiotic-type agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon-type agents, cyclooxygenase inhibitors (e.g.
• COX-2 inhibitors COX-2 inhibitors
• metallomatrixprotease inhibitors telomerase inhibitors
• tyrosine kinase inhibitors anti- growth factor receptor agents, anti-HER agents, anti-EGFR agents, anti-angiogenesis agents, farnesyl transferase inhibitors, ras-raf signal transduction pathway inhibitors, cell cycle inhibitors, other cdks inhibitors, tubulin binding agents, topoisomerase I inhibitors, topoisomerase II inhibitors, and the like.
• the compounds of the invention can be administered in combination with one or more chemotherapeutic agents such as, for instance, taxane, taxane derivatives, encapsulated taxanes, CPT-11, camptothecin derivatives, anthracycline glycosides, e.g., doxorubicin, idarubicin, epirubicin, etoposide, navelbine, vinblastine, carboplatin, cisplatin, estramustine, celecoxib, Sugen SU-5416, Sugen SU-6668, Herceptin, and the like, optionally within liposomal formulations thereof.
• chemotherapeutic agents such as, for instance, taxane, taxane derivatives, encapsulated taxanes, CPT-11, camptothecin derivatives, anthracycline glycosides, e.g., doxorubicin, idarubicin, epirubicin, etoposide, navelbine, vinblastine,
• such combination products employ the compounds of this invention within the dosage range described above and the other pharmaceutically active agent within the approved dosage range.
• the compounds of the invention can be administered in a variety of dosage forms, e.g. orally, in the form of tablets, capsules, sugar or film coated tablets, liquid solutions or suspensions; rectally in the form of suppositories; parenterally, e.g. intramuscularly, or by intravenous and/or intrathecal and/or intraspinal injection or infusion.
• the present invention also includes pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof in association with a pharmaceutically acceptable excipient (which can be a carrier or a diluent).
• a pharmaceutically acceptable excipient which can be a carrier or a diluent.
• compositions containing the compounds of the invention are usually prepared following conventional methods and are administered in a pharmaceutically suitable form.
• the solid oral forms may contain, together with the active compound, diluents, e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch; lubricants, e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols; binding agents, e.g. starches, arable gum, gelatins, methylcellulose, carboxymethylcellulose or polyvinyl pyrrolidone; disaggregating agents, e.g.
• diluents e.g. lactose, dextrose, saccharose, sucrose, cellulose, corn starch or potato starch
• lubricants e.g. silica, talc, stearic acid, magnesium or calcium stearate, and/or polyethylene glycols
• binding agents e.g. starches, arable gum, gelatins, methylcellulose, carboxymethylcellulose or poly
• Said pharmaceutical preparations may be manufactured in known manner, for example, by means of mixing, granulating, tableting, sugar-coating, or film-coating processes.
• liquid dispersions for oral administration may be e.g. syrups, emulsions and suspensions.
• the syrups may contain as carrier, for example, saccharose or saccharose with glycerine and/or mannitol and/or sorbitol.
• the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose, or polyvinyl alcohol.
• the suspension or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier, e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.
• a pharmaceutically acceptable carrier e.g. sterile water, olive oil, ethyl oleate, glycols, e.g. propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.
• the solutions for intravenous injections or infusions may contain as carrier, for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.
• carrier for example, sterile water or preferably they may be in the form of sterile, aqueous, isotonic saline solutions or they may contain as a carrier propylene glycol.
• the suppositories may contain together with the active compound a pharmaceutically acceptable carrier, e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
• a pharmaceutically acceptable carrier e.g. cocoa butter, polyethylene glycol, a polyoxyethylene sorbitan fatty acid ester surfactant or lecithin.
• the resin was then resuspended in 10 ml of dichioromethane and 232 mg (1.88 mmol) of 3-cyclopropyl-5-aminopyrazole were added. After 12 hours under stirring the resin was collected by filtration and washed with methanol. After drying in the vacuum oven, 1.097 g of resin were obtained. Analysis by FT-IR showed a strong carbonyl stretch at 1761 cm "1 .
• oxime-carbamate resin (XVIII) was suspended in 1 ml of DMSO and 11 mg (0.08 mmol) of 3-methoxybenzylamine in 0.2 M DMSO solution were added. The reaction was heated at 80°C for three hours, then the resin was separated by filtration, washed with 150 ⁇ l of dichioromethane and 150 ⁇ l of MeOH. The filtrate was concentrated to give, after trituration with diethylether 11.4 mg (50% yield) of the title compound.
• N-(3-cyclopropyl-lH-pyrazol-5-ylVN'-(1.3-benzodioxol-5-yl-methyl)urea To a solution of 1.5 g (6.7 mmol) of tert-butyl-3-amino-5-cyclopropyl-lH-pyrazole-l- carboxylate in 15 ml of dichioromethane under nitrogen 1.41 g (7 mmol) of p- nitrophenylchloro formate in a mixture of 7 ml of dichioromethane and 1 ml of pyridine were added dropwise at 0°C.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Epidemiology (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Urology & Nephrology (AREA)
• Heart & Thoracic Surgery (AREA)
• Vascular Medicine (AREA)
• Cardiology (AREA)
• Oncology (AREA)
• Dermatology (AREA)
• Pulmonology (AREA)
• Immunology (AREA)
• Orthopedic Medicine & Surgery (AREA)
• Rheumatology (AREA)
• Physical Education & Sports Medicine (AREA)
• Hematology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)

Priority Applications (15)

Applications Claiming Priority (2)

Publications (1)

Family

ID=23469810

Family Applications (1)

Country Status (25)

Cited By (55)

Families Citing this family (22)

Citations (1)

Family Cites Families (5)

• 1999
  • 1999-08-12 US US09/372,833 patent/US6387900B1/en not_active Expired - Fee Related
• 2000
  • 2000-08-03 PE PE2000000771A patent/PE20010482A1/es not_active Application Discontinuation
  • 2000-08-10 AR ARP000104118A patent/AR035557A1/es unknown
  • 2000-08-10 CO CO00059913A patent/CO5200848A1/es not_active Application Discontinuation
  • 2000-08-11 SK SK208-2002A patent/SK2082002A3/sk unknown
  • 2000-08-11 DE DE60034683T patent/DE60034683T2/de not_active Expired - Fee Related
  • 2000-08-11 CN CN00812736A patent/CN1379668A/zh active Pending
  • 2000-08-11 CA CA002380786A patent/CA2380786A1/en not_active Abandoned
  • 2000-08-11 AU AU67470/00A patent/AU6747000A/en not_active Abandoned
  • 2000-08-11 AT AT00955241T patent/ATE361070T1/de not_active IP Right Cessation
  • 2000-08-11 EA EA200200249A patent/EA200200249A1/ru unknown
  • 2000-08-11 KR KR1020027001815A patent/KR20020060158A/ko not_active Withdrawn
  • 2000-08-11 IL IL14792500A patent/IL147925A0/xx unknown
  • 2000-08-11 BR BR0013277-2A patent/BR0013277A/pt not_active Application Discontinuation
  • 2000-08-11 WO PCT/US2000/017878 patent/WO2001012188A1/en not_active Ceased
  • 2000-08-11 JP JP2001516534A patent/JP2003507328A/ja not_active Withdrawn
  • 2000-08-11 ES ES00955241T patent/ES2284518T3/es not_active Expired - Lifetime
  • 2000-08-11 NZ NZ517238A patent/NZ517238A/en unknown
  • 2000-08-11 EP EP00955241A patent/EP1202734B1/en not_active Expired - Lifetime
  • 2000-08-11 HU HU0301857A patent/HUP0301857A2/hu unknown
  • 2000-08-11 PL PL00354058A patent/PL354058A1/xx not_active Application Discontinuation
  • 2000-08-11 HK HK03101874.6A patent/HK1049790A1/zh unknown
  • 2000-08-11 MX MXPA02001497A patent/MXPA02001497A/es active IP Right Grant
• 2002
  • 2002-02-08 ZA ZA200201118A patent/ZA200201118B/en unknown
  • 2002-02-11 NO NO20020687A patent/NO20020687L/no not_active Application Discontinuation

Patent Citations (1)

Also Published As

Similar Documents

Legal Events